Featured Research

from universities, journals, and other organizations

Dosage Appears To Be A Critical Factor In Cocaine Vaccine

Date:
January 29, 2002
Source:
Yale University
Summary:
Dosage appears to be a critical factor in the effectiveness of a cocaine vaccine being tested by Yale researchers that is designed to block the euphoria drug abusers experience.

New Haven, Conn. – Dosage appears to be a critical factor in the effectiveness of a cocaine vaccine being tested by Yale researchers that is designed to block the euphoria drug abusers experience.

Of eight patients in the second phase of clinical trials of the vaccine, one received one dose and the others received three to four doses. Six of the eight patients reported only one or two uses of cocaine during six months of follow up treatment and the two other patients used cocaine on a regular basis during the six months.

"These are very good results for people who abuse cocaine," said Thomas Kosten, M.D., professor of psychiatry at Yale School of Medicine and lead researcher on the project. There are an estimated three million cocaine abusers, making cocaine the second most commonly abused illicit drug after marijuana.

Kosten hopes to enroll a total of 150 patients in the second phase of the trial. The goal in this next stage, which is being conducted on an out patient basis, is to determine the dosage and the degree of addiction.

The first phase of the clinical trial included 34 subjects and was intended to test how the vaccine worked, whether it was safe, and if there were any side effects. Kosten published the results of the Phase One trial in the January issue of the journal Vaccine.

"We found that the vaccine, TA-CD, is safe, made antibodies, and there is no significant toxicity," he said. "The vaccine was well tolerated and had no serious drug-related adverse events, although three subjects at the highest dose experienced brief post injection twitching at the injection site. We’re now trying to get some sense of whether we can increase the frequency of dosing to perhaps five times to see if we can get the level of antibodies even higher."

The 34 subjects enrolled in the Phase One trial were abstinent cocaine abusers who were confined in a residential drug treatment program. Of that number, 27 completed the full course of three monthly injections. Of these, 24 returned for the final scheduled visit after three months. Fifteen of those inoculated were followed for one year.

"Anti-cocaine antibodies were detected after the second injection, peaked at three months, and declined to baseline by one year," Kosten said.

The vaccine works by binding the cocaine to antibodies on entering the bloodstream, preventing uptake of cocaine across the blood-brain barrier and dulling or even obliterating the euphoric rush.

Kosten said the vaccine probably only will be effective for those drug abusers who are motivated to stop using cocaine because someone intent on getting high can override the vaccine’s binding action by taking more cocaine.

Since just a small amount of cocaine stimulates intense craving for more of the substance, leading to a binge, he said the vaccine may be most effective at reducing this priming effect. "The vaccine may be able to prevent a cocaine slip from turning into a full scale binge and relapse to dependence," Kosten said.

The research is funded by the National Institute on Drug Abuse. The vaccine is being developed by Xenova Pharmaceuticals plc, a biopharmaceutical company based in Cambridge, England.


Story Source:

The above story is based on materials provided by Yale University. Note: Materials may be edited for content and length.


Cite This Page:

Yale University. "Dosage Appears To Be A Critical Factor In Cocaine Vaccine." ScienceDaily. ScienceDaily, 29 January 2002. <www.sciencedaily.com/releases/2002/01/020129073358.htm>.
Yale University. (2002, January 29). Dosage Appears To Be A Critical Factor In Cocaine Vaccine. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2002/01/020129073358.htm
Yale University. "Dosage Appears To Be A Critical Factor In Cocaine Vaccine." ScienceDaily. www.sciencedaily.com/releases/2002/01/020129073358.htm (accessed July 25, 2014).

Share This




More Mind & Brain News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

University Quiz Implies Atheists Are Smarter Than Christians

University Quiz Implies Atheists Are Smarter Than Christians

Newsy (July 25, 2014) An online quiz from a required course at Ohio State is making waves for suggesting atheists are inherently smarter than Christians. Video provided by Newsy
Powered by NewsLook.com
Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins